Cisplatin nephrotoxicity: A multivariate analysis of potential predisposing factors

Pharmacotherapy

Volumn 17, Issue 6, 1997, Pages 1246-1253

  Lagrange, Jean Leon ^a   Médecin, Blandine ^a   Etienne, Marie Christine ^a   Pivot, Xavier ^c   Cassuto Viguier, Elisabeth ^b   Renée, Nicole ^a   Thyss, Antoine ^a   Ferrero, Jean Marc ^a   Otto, Josiane ^a   François, Eric ^a   Milano, Gérard ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b PASTEUR HOSPITAL   (France)

^c Centre Antoine Lacassagne ^*

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CREATININE; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; NAVELBINE; PLATINUM; VINBLASTINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CREATININE CLEARANCE; DIGESTIVE SYSTEM CANCER; DISEASE PREDISPOSITION; DRUG BLOOD LEVEL; ESOPHAGUS CANCER; FEMALE; HEAD AND NECK CANCER; HIGH RISK PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PANCREAS CANCER; PROSPECTIVE STUDY; REGRESSION ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CISPLATIN; FEMALE; HUMANS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLATINUM; PROSPECTIVE STUDIES;

EID: 1842408428     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Von Hoff DD, Schilsky R, Reichert CM, et al. Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep 1979;63:1527-31.
2. Brock J, Alberts DS. Safe, rapid administration of cisplatin in the outpatient clinic. Cancer Treat Rep 1986;70:1409-14.
3. Daugaard G, Abildgaard U. Cisplatin nephrotoxicity. Cancer Chemother Pharmacol 1989;25:1-9.
4. Fjeldborg P, Sorensen J, Helkjaer P. The long-term effect of cisplatin on renal function. Cancer 1986;58:2214-17.
5. Groth S, Nielsen H, Sorensen JB, Christensen AB, Pedersen AG, Rorth M. Acute and long-term nephrotoxicity of cis-platinum in man. Cancer Chemother Pharmacol 1986;17:191-6.
6. Hamilton CR, Bliss JM, Horwich A. The late effects of cis-platinum on renal function. Eur J Cancer Clin Oncol 1989;25:185-9.
7. Pinzani V, Bressolle F, Hang IJ, Galtier M, Blayac JP, Balmes P. Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother Pharmacol 1994;35:1-9.
8. Campbell AB, Kalman SM, Jacobs C. Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity. Cancer Treat Rep 1983;67:169-72.
9. Kelsen DP, Alcock N, Young CW. Cisplatin nephrotoxicity. Correlation with plasma platinum concentrations. Am J Clin Oncol 1985;8:77-80.
10. Reece PA, Stafford I, Russel J, Khan M, Gill PG. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 1987;5:304-9.
11. Reece PA, Stafford I, Davy M, Morris R, Freeman S. Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancer. Cancer Chemother Pharmacol 1989;24:256-60.
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-42.
13. Fournier C, Vennin P, Hecquet B. Correlation between free platinum AUC and total platinum measurement 24 h after i.v. bolus injection of cisplatin in humans. Cancer Chemother Pharmacol 1988;21:75-7.
14. Bodenner DL, Dedon PC, Keng PC, Katz JC, Borch RF. Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut and bone marrow by diethyldithiocarbamate. Cancer Res 1986;46:2751-6.
15. Daugaard G, Abildgaard U, Holstein-Rathlou NH, Bruunshuus I, Bucher D, Leyssac PP. Renal tubular function in patients treated with high-dose cisplatin. Clin Pharmacol Ther 1988;44:164-72.
16. Teeling M, Pratt I, Casez B, Ryan MP, Carney DN. N-acetyl-β-D glucosaminidase as an early indicator of renal tissular dysfunction on cisplatin nephrotoxicity. Proc Am Soc Clin Oncol 1986;5:52.
17. Forastière AA, Belliveau JF, Goren MP, Vogel WC, Posner MR, O'Leary GP. Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum(II) in head and neck cancer patients. Cancer Res 1988;48:3869-74.
18. Erlichman C, Soldin SJ, Thiessen JJ, Strugeon JFG, Fine S. Disposition of total and free cisplatin on two consecutive treatment cycles in patients with ovarian cancer. Cancer Chemother Pharmacol 1987;19:75-9.
19. Reece PA, Stafford I, Russel J, Gill PG. Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatin. J Clin Oncol 1986;4:1392-8.
20. Tothill P, Klys AS, Matheson LM, McKay K, Smyth JF. The long-term retention of platinum in human tissues following the administration of cisplatin and carboplatin for cancer chemotherapy. Eur J Cancer 1992;28:1358-61.
21. Schierl R, Rohrer B, Hohnloser J. Long-term platinum excretion in patients treated with cisplatin. Cancer Chemother Pharmacol 1995;36:75-8.
22. Thyss A, Saudes L, Otto J, et al. Renal tolerance of cisplatin in patients more than 80 years old. J Clin Oncol 1994;12:2121-5.
23. Lagrange JL, Cassuto-Viguier E, Barbé V, et al. Cytotoxic effects of long-term circulating ultrafilterable platinum species and limited efficacy of haemodialysis to clear them. Eur J Cancer 1995;30:2057-60.
24. Ghazal-Aswad S, Calvert AH, Newell DR. A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve. Cancer Chemother Pharmacol 1996;37:429-32.
25. Nelson JA, Santos G, Herbert BH. Mechanisms for the renal secretion of cisplatin. Cancer Treat Rep 1984;68:849-53.
26. Tay LK, Bregman CL, Masters BA, Williams PD. Effects of cis-diamminedichloroplatinum(II) on rabbit kidney in vivo and on rabbit renal proximal tubule cells in culture. Cancer Res 1988;48:2538-43.